North East patients are among the first in the UK to trial Lutetium (177Lu) rhPSMA-10.1, a new targeted treatment for ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Thousands of men with prostate cancer will be offered a life-extending drug on the NHS within weeks. For the first time patients whose prostate cancer has not spread will be able to receive the drug ...

City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by ...

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. Subscribe to our ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 clinical study of pasritamig, a new cancer therapy ...

Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

A North Island College (NIC) biology instructor has received a $10,000 grant from Prostate Cancer Foundation Canada to give ...

Prostate Cancer UK said a 42 per cent rise in diagnoses in the past decade is thanks to increased awareness of the disease by ...